A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
Publication
, Conference
Bhardwaj, N; Ernstoff, M; Curti, B; Hanks, BA; Albertini, M; Luke, J; Yellin, M; Keler, T; Davis, T; Vitale, L; Crocker, A; Friedlander, P ...
Duke Scholars
Location
Chicago, IL
Conference Name
2016 American Society of Clinical Oncology Annual Meeting
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Bhardwaj, N., Ernstoff, M., Curti, B., Hanks, B. A., Albertini, M., Luke, J., … Fling, S. (n.d.). A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. Presented at the 2016 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Bhardwaj, N., M. Ernstoff, B. Curti, B. A. Hanks, M. Albertini, J. Luke, M. Yellin, et al. “A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand,” n.d.
Bhardwaj N, Ernstoff M, Curti B, Hanks BA, Albertini M, Luke J, et al. A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. In.
Bhardwaj N, Ernstoff M, Curti B, Hanks BA, Albertini M, Luke J, Yellin M, Keler T, Davis T, Vitale L, Crocker A, Friedlander P, Morishima C, Cheever M, Fling S. A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
Location
Chicago, IL
Conference Name
2016 American Society of Clinical Oncology Annual Meeting
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences